Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Antileukemic Activity of 8-Chloro-Adenosine (8-Cl-Ado) Is Mediated By Mir-155 Degradation and ErbB3 Binding Protein (Ebp1)-Dependent p53 Activation: A Novel Therapeutic Approach for FLT3-ITD Acute Myeloid Leukemia (AML)

Blood (2018) 132 (Supplement 1): 3938.

https://doi.org/10.1182/blood-2018-99-119880

Published: 2018

Journal Articles

Predictive Response Biomarkers for BET Inhibitors in AML

Joseph J Saad, MSc, BSc, Juho Miettinen, PhD, Dimitrios Tsallos, BSc(Hons),MSc, Samuli Eldfors, PhD, Mika Kontro, MD, Krister Wennerberg, PhD, Olli Kallioniemi, MD PhD, Kimmo Porkka, MD PhD, Jing Tang, PhD, Caroline A Heckman, PhD

Blood (2018) 132 (Supplement 1): 2749.

https://doi.org/10.1182/blood-2018-99-118363

Published: 2018

Journal Articles

Combined Targeting of BET Family Proteins and BCL2 Is Synergistic in Acute Myeloid Leukemia Cells Overexpressing S100A8 and S100A9

Riikka Karjalainen, Minxia Liu, Ashwini Kumar, MRes, Alun Parsons, Liye He, Dishaben Rameshbhai Malani, MSc, Mika Kontro, MD, Kimmo Porkka, MD PhD, Caroline A Heckman, PhD

Blood (2018) 132 (Supplement 1): 2634.

https://doi.org/10.1182/blood-2018-99-118890

Published: 2018

Journal Articles

Gene-Drug Interactions in AML Patients Identified By RNA Sequencing and Comprehensive Ex Vivo Drug Sensitivity and Resistance Testing

Ashwini Kumar, MRes, Dishaben Rameshbhai Malani, MSc, Bhagwan Yadav, PhD, Matti Kankainen, PhD, Swapnil Potdar, MSc, Mika Kontro, MD, Kimmo Porkka, MD PhD, Olli Kallioniemi, MD PhD, Simon Anders, PhD, Caroline A Heckman, PhD

Blood (2017) 130 (Supplement 1): 1398.

https://doi.org/10.1182/blood.V130.Suppl_1.1398.1398

Published: 2017

Journal Articles

Identification and Clinical Exploration of Individualized Targeted Therapeutic Approaches in Acute Myeloid Leukemia Patients By Integrating Drug Response and Deep Molecular Profiles

Disha Malani, MRes, Ashwini Kumar, MRes, Bhagwan Yadav, PhD, Mika Kontro, MD, Swapnil Potdar, MSc, Samuli Eldfors, MSc, Jani Saarela, Bjørn Tore Gjertsen, Riikka Karjalainen, Tero Aittokallio, Astrid Murumagi, Maija Wolf, PhD, Simon Anders, PhD, Krister Wennerberg, Caroline A Heckman, PhD, Kimmo Porkka, MD PhD, Olli Kallioniemi, MD PhD

Blood (2017) 130 (Supplement 1): 854.

https://doi.org/10.1182/blood.V130.Suppl_1.854.854

Published: 2017

Journal Articles

Single-Cell Drug Profiling Reveals Maturation Stage-Dependent Drug Responses in AML

Heikki Kuusanmäki, MSc, Maija Leppä, BSc, Mika Kontro, MD, Olli Dufva, BSc, Debashish Deb, MSc, Bhagwan Yadav, PhD, Satu Mustjoki, MDPhD, Kimmo Porkka, MD PhD, Caroline A Heckman, PhD

Blood (2017) 130 (Supplement 1): 3821.

https://doi.org/10.1182/blood.V130.Suppl_1.3821.3821

Published: 2017

Journal Articles

Elevated Expression of the S100A8/S100A9 Complex in AML Correlates with Reduced Sensitivity to the BCL2 Inhibitor Venetoclax

Riikka Karjalainen, Minxia Liu, Ashwini Kumar, MRes, Alun Parsons, Mika Kontro, MD, Kimmo Porkka, MD PhD, Caroline A Heckman, PhD

Blood (2017) 130 (Supplement 1): 298.

https://doi.org/10.1182/blood.V130.Suppl_1.298.298

Published: 2017

Journal Articles

8-Chloro-Adenosine Inhibits Molecular Poor-Risk Acute Myeloid Leukemia (AML) and Leukemic Stem Cells (LSC) Growth and Synergizes with the BCL-2 Inhibitor Venetoclax (ABT-199)

Ralf Buettner, PhD, Ching-Cheng Chen, PhD, Bijender Kumar, PhD, Corey Morales, BA, BS, Lisa S Chen, PhD, Krister Wennerberg, PhD, Ryan Thompson, MS, Tea Pemovska, MSc, Ling Li, PhD, Bin Zhang, PhD, Claudia Kowolik, PhD, Mika Kontro, MD, Calum Leitch, MD, David Horne, PhD, Joycelynne Palmer, PhD, Varsha Gandhi, PhD, Guido Marcucci, MD, Vinod Pullarkat, MD, Steven T. Rosen, MD

Blood (2016) 128 (22): 2758.

https://doi.org/10.1182/blood.V128.22.2758.2758

Published: 2016

Journal Articles

Identification of Optimized Compound Combinations for the Treatment of NUP98-NSD1+ AML

Jarno Kivioja, MSc, Angeliki Thanasopoulou, PhD, Mika Kontro, MD, Bhagwan Yadav, MSc, Muntasir Mamun Majumder, MSc, Heikki Kuusanmäki, MSc, Alun Parsons, MSc, Kimmo Porkka, MD PhD, Juerg Schwaller, MD, Caroline A Heckman, PhD

Blood (2016) 128 (22): 4711.

https://doi.org/10.1182/blood.V128.22.4711.4711

Published: 2016

Journal Articles

BCL2-Inhibitors Target a Major Group of Newly-Diagnosed and Relapsed/Refractory Acute Myeloid Leukemia Ex Vivo

Mika Kontro, MD, Samuli Eldfors, MSc, Muntasir Mamun Majumder, MSc,MPharm, Alun Parsons, MSc, Tea Pemovska, MSc, Olli Kallioniemi, MD PhD, Krister Wennerberg, PhD, Caroline A Heckman, PhD, Kimmo Porkka, MD PhD

Blood (2015) 126 (23): 2462.

https://doi.org/10.1182/blood.V126.23.2462.2462

Published: 2015

Journal Articles

A Profound Biological Difference of Chronic and Blast Phase Chronic Myeloid Leukemia in Ex Vivo Drug Responses

Paavo Pietarinen, MSc, Tea Pemovska, MSc, Emma I Andersson, MSc, Perttu Koskenvesa, MD, Mika Kontro, MD, Swapnil Potdar, MSc, John Patrick Mpindi, MSc, Olli Kallioniemi, MD PhD, Krister Wennerberg, PhD, Caroline A Heckman, PhD, Satu Mustjoki, MDPhD, Kimmo Porkka, MD PhD

Blood (2014) 124 (21): 3139.

https://doi.org/10.1182/blood.V124.21.3139.3139

Published: 2014

Journal Articles

Analysis of Clonal Evolution in Chemorefractory Acute Myeloid Leukemia from Diagnosis to Relapse

Naga Poojitha Ojamies, MSc, Mika Kontro, MD, Maija Wolf, PhD, Henrik Edgren, PhD, Pekka Ellonen, MSc, Sonja Lagström, MSc, Tiina Hannunen, MSc, Tea Pemovska, MSc, Henrikki Almusa, MSc, Maija Lepistö, MSc, Caroline A Heckman, PhD, Krister Wennerberg, PhD, Kimmo Porkka, MD PhD, Olli Kallioniemi, MD PhD

Blood (2014) 124 (21): 1022.

https://doi.org/10.1182/blood.V124.21.1022.1022

Published: 2014

Journal Articles

Stroma-Derived Factors Significantly Impact the Drug Response Profiles of Patient-Derived Primary AML Cells: Implications for Drug Sensitivity Testing

Riikka Karjalainen, MSc, Tea Pemovska, MSc, Muntasir Mamun Majumder, MSc, David Tamborero, PhD, Bhagwan Yadav, MSc, Mika Kontro, MD, Bjørn Gjertsen, MD PhD, Alun Parsons, MSc, Minna Suvela, BSc, Tero Aittokallio, PhD, Kimmo Porkka, MD PhD, Olli Kallioniemi, MD PhD, Krister Wennerberg, PhD, Caroline A Heckman, PhD

Blood (2014) 124 (21): 3505.

https://doi.org/10.1182/blood.V124.21.3505.3505

Published: 2014

Journal Articles

Landscape of Mutations in Relapsed Acute Myeloid Leukemia

Samuli Eldfors, MSc, Mika Kontro, MD, Kimmo Porkka, MD PhD, Olli Kallioniemi, MD PhD, Caroline Heckman, PhD

Blood (2014) 124 (21): 2367.

https://doi.org/10.1182/blood.V124.21.2367.2367

Published: 2014

Journal Articles

Identification of Novel Therapeutic Strategies for NUP98-NSD1-Positive AML By Drug Sensitivity Profiling

Jarno Kivioja, MSc, Mika Kontro, MD, Angeliki Thanasopoulou, PhD, Muntasir Mamun Majumder, MSc,BPharm, Bhagwan Yadav, MSc, Heikki Kuusanmäki, MSc, Alun Parsons, MSc, Juerg Schwaller, MD, Kimmo Porkka, MD PhD, Caroline A Heckman, PhD

Blood (2014) 124 (21): 2160.

https://doi.org/10.1182/blood.V124.21.2160.2160

Published: 2014

Journal Articles

AML Specific Targeted Drugs Identified By Drug Sensitivity and Resistance Testing: Comparison of Ex Vivo Patient Cells with in Vitro Cell Lines

Disha Malani, MSc, Astrid Murumägi, PhD, Bhagwan Yadav, MSc, Tea Pemovska, MSc, John Patrick Mpindi, MSc, Mika Kontro, MD, Tero Aittokallio, PhD, Caroline A Heckman, PhD, Kimmo Porkka, MD PhD, Krister Wennerberg, PhD, Maija Wolf, PhD, Olli Kallioniemi, MD PhD

Blood (2014) 124 (21): 2163.

https://doi.org/10.1182/blood.V124.21.2163.2163

Published: 2014

Journal Articles

Stromal Cell Supported High-Throughput Drug Testing Of Primary Leukemia Cells For Comprehensive Assessment Of Sensitivity To Novel Therapies

Riikka Karjalainen, MSc, Tea Pemovska, MSc, Bhagwan Yadav, MSc, Muntasir Mamun Majumder, MSc, Mika Kontro, MD, Kimmo Porkka, MD, PhD, Olli Kallioniemi, MD, PhD, Tero Aittokallio, PhD, Krister Wennerberg, PhD, Caroline A Heckman, PhD

Blood (2013) 122 (21): 1668.

https://doi.org/10.1182/blood.V122.21.1668.1668

Published: 2013

Journal Articles

Novel Activating STAT5B Mutations As Drivers Of T-ALL

Mika Kontro, MD, Heikki Kuusanmäki, MSc, Samuli Eldfors, MSc, Tea Pemovska, MSc, Hanna L M Rajala, MD, Henrik Edgren, PhD, Pekka Ellonen, MSc, Sonja Lagström, MSc, Tuija Lundán, PhD, Olli Kallioniemi, MD, PhD, Satu Mustjoki, MD, PhD, Kimmo Porkka, MD, PhD, Caroline Heckman, PhD

Blood (2013) 122 (21): 3863.

https://doi.org/10.1182/blood.V122.21.3863.3863

Published: 2013

Journal Articles

Identification Of AML Subtype-Selective Drugs By Functional Ex Vivo Drug Sensitivity and Resistance Testing and Genomic Profiling

Blood (2013) 122 (21): 482.

https://doi.org/10.1182/blood.V122.21.482.482

Published: 2013

Journal Articles

High-Throughput Ex Vivo Drug Sensitivity and Resistance Testing (DSRT) Integrated with Deep Genomic and Molecular Profiling Reveal New Therapy Options with Targeted Drugs in Subgroups of Relapsed Chemorefractory AML

Blood (2012) 120 (21): 288.

https://doi.org/10.1182/blood.V120.21.288.288

Published: 2012

NARROW

Antileukemic Activity of 8-Chloro-Adenosine (8-Cl-Ado) Is Mediated By Mir-155 Degradation and ErbB3 Binding Protein (Ebp1)-Dependent p53 Activation: A Novel Therapeutic Approach for FLT3-ITD Acute Myeloid Leukemia (AML)

Predictive Response Biomarkers for BET Inhibitors in AML

Combined Targeting of BET Family Proteins and BCL2 Is Synergistic in Acute Myeloid Leukemia Cells Overexpressing S100A8 and S100A9

Gene-Drug Interactions in AML Patients Identified By RNA Sequencing and Comprehensive Ex Vivo Drug Sensitivity and Resistance Testing

Identification and Clinical Exploration of Individualized Targeted Therapeutic Approaches in Acute Myeloid Leukemia Patients By Integrating Drug Response and Deep Molecular Profiles

Single-Cell Drug Profiling Reveals Maturation Stage-Dependent Drug Responses in AML

Elevated Expression of the S100A8/S100A9 Complex in AML Correlates with Reduced Sensitivity to the BCL2 Inhibitor Venetoclax

8-Chloro-Adenosine Inhibits Molecular Poor-Risk Acute Myeloid Leukemia (AML) and Leukemic Stem Cells (LSC) Growth and Synergizes with the BCL-2 Inhibitor Venetoclax (ABT-199)

Identification of Optimized Compound Combinations for the Treatment of NUP98-NSD1+ AML

BCL2-Inhibitors Target a Major Group of Newly-Diagnosed and Relapsed/Refractory Acute Myeloid Leukemia Ex Vivo

A Profound Biological Difference of Chronic and Blast Phase Chronic Myeloid Leukemia in Ex Vivo Drug Responses

Analysis of Clonal Evolution in Chemorefractory Acute Myeloid Leukemia from Diagnosis to Relapse

Stroma-Derived Factors Significantly Impact the Drug Response Profiles of Patient-Derived Primary AML Cells: Implications for Drug Sensitivity Testing

Landscape of Mutations in Relapsed Acute Myeloid Leukemia

Identification of Novel Therapeutic Strategies for NUP98-NSD1-Positive AML By Drug Sensitivity Profiling

AML Specific Targeted Drugs Identified By Drug Sensitivity and Resistance Testing: Comparison of Ex Vivo Patient Cells with in Vitro Cell Lines

Stromal Cell Supported High-Throughput Drug Testing Of Primary Leukemia Cells For Comprehensive Assessment Of Sensitivity To Novel Therapies

Novel Activating STAT5B Mutations As Drivers Of T-ALL

Identification Of AML Subtype-Selective Drugs By Functional Ex Vivo Drug Sensitivity and Resistance Testing and Genomic Profiling

High-Throughput Ex Vivo Drug Sensitivity and Resistance Testing (DSRT) Integrated with Deep Genomic and Molecular Profiling Reveal New Therapy Options with Targeted Drugs in Subgroups of Relapsed Chemorefractory AML

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only